Physician profile
Divya Shah
NPI 1316343643
$3,840.89
in general payments reported to CMS, 2019-2025
27 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $154 · 2021: $213 · 2022: $912 · 2023: $1,206 · 2024: $827 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.96 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $536.79 | 2019-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $450.92 | 2022-2025 | Caplyta |
| Lundbeck LLC | $337.38 | 2019-2024 | Rexulti |
| Alkermes, INC. | $281.82 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $261.37 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $253.84 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $193.59 | 2022-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $124.03 | 2019-2023 | Ingrezza |
| Corium, LLC | $123.38 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $85.68 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $85.40 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $67.75 | 2023-2024 | Quviviq |
| Allergan, INC. | $54.21 | 2020 | |
| Supernus Pharmaceuticals, INC. | $50.50 | 2023-2024 | Qelbree, Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $47.61 | 2019 | |
| Vertical Pharmaceuticals, LLC | $46.01 | 2024 | Relexxii |
| Vanda Pharmaceuticals INC. | $45.75 | 2020-2024 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $28.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.40 | 2024 | Cobenfy |
| Medtronic, INC. | $26.69 | 2024 | Interstim |
| Bausch Health US, LLC | $24.67 | 2022 | |
| Neos Therapeutics, LP | $19.03 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $17.70 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $16.65 | 2023 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $14.77 | 2022 | |
| Smith+Nephew, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.